Zobrazeno 1 - 10
of 22
pro vyhledávání: '"J. Oborski"'
Autor:
J. Oborski, Esther Kurth, Earl Mcdonald, Florencia Rago, Audrey Kauffmann, Jessi Ambrose, Zainab Jagani, Kathleen Sprouffske, Lindsey Rodrigues, Peter Aspesi, Julie T. Chen, Felipa A. Mapa, Tinya Abrams, Hyo-eun C. Bhang, David A. Ruddy, GiNell Elliott, M. Bonney
Publikováno v:
Molecular Cancer Research. 20:361-372
Various subunits of mammalian SWI/SNF chromatin remodeling complexes display loss-of-function mutations characteristic of tumor suppressors in different cancers, but an additional role for SWI/SNF supporting cell survival in distinct cancer contexts
Autor:
Binsheng Zhao, Milan Grkovski, Charles M. Laymon, John Sunderland, Ghassan Hamarneh, Dmitry B. Goldgof, Brian J. Smith, Sadek Nehmeh, John P. Muzi, Reinhard Beichel, Payam Ahmadvand, Matthew J. Oborski, Mark Muzi, Ethan J. Ulrich, Christian Bauer, Robert J. Gillies, James M. Mountz, Mikalai M. Budzevich, Paul E. Kinahan, John M. Buatti
Publikováno v:
Tomography
Volume 6
Issue 2
Pages 65-76
Tomography; Volume 6; Issue 2; Pages: 65-76
Volume 6
Issue 2
Pages 65-76
Tomography; Volume 6; Issue 2; Pages: 65-76
Quantitative imaging biomarkers (QIBs) provide medical image–derived intensity, texture, shape, and size features that may help characterize cancerous tumors and predict clinical outcomes. Successful clinical translation of QIBs depends on the robu
Autor:
Charles M. Laymon, Matthew J. Oborski, Julie C. Price, James M. Mountz, Carl Becker, Cristy Matan, Davneet S. Minhas
Publikováno v:
Molecular Imaging and Biology. 20:826-834
PURPOSE: In dual modality Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI), attenuation correction (AC) methods are continually improving. Although a new AC can sometimes be generated from existing MR data, its application requires
Autor:
Thomas L. Chenevert, Brendan Moloney, Matthew J. Oborski, Kathleen M. Schmainda, Jayashree Kalpathy-Cramer, Guido H. Jajamovich, Kourosh Jafari-Khouzani, Madhava P. Aryal, Yue Cao, Peter S. LaViolette, Sandeep N. Gupta, Bachir Taouli, Mark Muzi, Andriy Fedorov, James M. Mountz, Paul E. Kinahan, Finbarr O'Sullivan, Wei Huang, Yiyi Chen, Aneela Afzal, Dariya I. Malyarenko, Alina Tudorica, Xin Li, Fiona M. Fennessy, Cecilia Besa, Richard G. Abramson, Thomas E. Yankeelov, Charles M. Laymon, Xia Li
Publikováno v:
Tomography; Volume 5; Issue 1; Pages: 99-109
Tomography
Volume 5
Issue 1
Pages 99-109
Tomography
Volume 5
Issue 1
Pages 99-109
This multicenter study evaluated the effect of variations in arterial input function (AIF) determination on pharmacokinetic (PK) analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data using the shutter-speed model (SSM). Data
Autor:
Charles M. Laymon, Frank S. Lieberman, Ronald L. Hamilton, Matthew J. Oborski, Jan Drappatz, James M. Mountz
Publikováno v:
Brain and Behavior
Objectives The authors present the first use of the novel positron emission tomography (PET) apoptosis tracer 18F-labeled 2-(5-fluoro-pentyl)-2-methyl-malonic acid (18F-ML-10) for early-therapy response assessment of a newly diagnosed glioblastoma mu
Autor:
Thomas L. Chenevert, Xia Li, Paul E. Kinahan, Matthew J. Oborski, James M. Mountz, Thomas E. Yankeelov, Andriy Fedorov, Ming-Ching Chang, Charles M. Laymon, James V. Miller, Fiona M. Fennessy, Xin Li, Jayashree Kalpathy-Cramer, Yiyi Chen, Alina Tudorica, Ron Kikinis, Bachir Taouli, Guido H. Jajamovich, Mark Muzi, Daniel P. Barbodiak, Kenneth I. Marro, Hadrien A. Dyvorne, Wei Huang, Sandeep N. Gupta, Dariya I. Malyarenko
Publikováno v:
Translational Oncology. 7:153-166
Pharmacokinetic analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) time-course data allows estimation of quantitative parameters such as K (trans) (rate constant for plasma/interstitium contrast agent transfer), v e (extravasc
Autor:
Charles M. Laymon, Matthew J. Oborski, Jan Drappatz, Yongxian Qian, James M. Mountz, Frank S. Lieberman
Publikováno v:
Tomography; Volume 2; Issue 4; Pages: 317-324
Tomography
Volume 2
Issue 4
Pages 317-324
Tomography
Volume 2
Issue 4
Pages 317-324
The ability to assess tumor apoptotic response to therapy could provide a direct and prompt measure of therapeutic efficacy. 18F-labeled 2-(5-fluoro-pentyl)-2-methyl-malonic acid ([18F]ML-10) is proposed as a positron emission tomography (PET) apopto
Publikováno v:
Clinical Nuclear Medicine. 38:381-384
We report a case in which 18F-FDG PET was able to discriminate pseudoprogression from progression observed on contrast-enhanced (CE) MRI (CE-MRI). A 56-year-old male patient with anaplastic oligodendroglioma demonstrated markedly increased tumor enha
Publikováno v:
Molecular Imaging and Radionuclide Therapy, Vol 21, Iss 3, Pp 91-96 (2012)
Molecular Imaging and Radionuclide Therapy
Molecular Imaging and Radionuclide Therapy
Objective: To assess the clinical utility of SPECT/ CT in subjects with endocrine and neuroendocrine tumors compared to SPECT alone. Material and Methods: 48 subjects (31 women;17 men; mean age 54±11) with clinical suspicion or diagnosis of endocrin
Autor:
Charles M. Laymon, Erik C. Wiener, Matthew J. Oborski, Frank S. Lieberman, James M. Mountz, Fernando E. Boada, Denise Davis, Vincent Lee
Publikováno v:
Magnetic Resonance Imaging. 30:1268-1278
We evaluate novel magnetic resonance imaging (MRI) and positron emission tomography (PET) quantitative imaging biomarkers and associated multimodality, serial-time-point analysis methodologies, with the ultimate aim of providing clinically feasible,